| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression profiling predicts clinical outcome of prostate cancer.
|
J Clin Invest
|
2004
|
4.59
|
|
2
|
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
|
Eur Urol
|
2013
|
3.41
|
|
3
|
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
|
J Urol
|
2011
|
3.36
|
|
4
|
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
|
Eur Urol
|
2007
|
2.31
|
|
5
|
Surgical resection of renal cell carcinoma after targeted therapy.
|
J Urol
|
2009
|
2.29
|
|
6
|
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era.
|
J Urol
|
2012
|
2.24
|
|
7
|
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.
|
J Clin Oncol
|
2010
|
2.14
|
|
8
|
Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder.
|
Eur Urol
|
2009
|
2.13
|
|
9
|
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment.
|
Urology
|
2011
|
2.12
|
|
10
|
Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
|
Urology
|
2011
|
2.07
|
|
11
|
High-risk prostate cancer: from definition to contemporary management.
|
Eur Urol
|
2012
|
2.06
|
|
12
|
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
|
Cancer
|
2009
|
2.02
|
|
13
|
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management.
|
Urology
|
2011
|
1.78
|
|
14
|
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy.
|
Cancer
|
2010
|
1.77
|
|
15
|
Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
|
Urology
|
2008
|
1.71
|
|
16
|
Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations.
|
Urology
|
2004
|
1.47
|
|
17
|
Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi.
|
Urology
|
2009
|
1.47
|
|
18
|
Prostate cancer volume at biopsy predicts clinically significant upgrading.
|
J Urol
|
2008
|
1.35
|
|
19
|
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
|
Urology
|
2008
|
1.32
|
|
20
|
Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases.
|
Am J Surg Pathol
|
2007
|
1.26
|
|
21
|
Histopathologic features and clinical outcomes in 71 cases of bladder diverticula.
|
Arch Pathol Lab Med
|
2009
|
1.19
|
|
22
|
Association of Mycoplasma hominis infection with prostate cancer.
|
Oncotarget
|
2011
|
1.19
|
|
23
|
Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.16
|
|
24
|
Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
|
J Urol
|
2008
|
1.13
|
|
25
|
The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival.
|
J Urol
|
2008
|
1.10
|
|
26
|
The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy.
|
Eur Urol
|
2009
|
1.08
|
|
27
|
Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder.
|
Urology
|
2011
|
1.04
|
|
28
|
Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?
|
Nat Rev Urol
|
2011
|
1.00
|
|
29
|
Robot-assisted laparoscopic retroperitoneal lymph node dissection for left clinical stage I non-seminomatous germ cell testicular cancer: focus on port placement and surgical technique.
|
Int J Urol
|
2013
|
0.99
|
|
30
|
Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
|
BJU Int
|
2009
|
0.99
|
|
31
|
When serial prostate biopsy is recommended: most cancers detected are clinically insignificant.
|
BJU Int
|
2012
|
0.97
|
|
32
|
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder.
|
Hum Pathol
|
2008
|
0.97
|
|
33
|
Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer.
|
Urol Oncol
|
2008
|
0.94
|
|
34
|
Management of clinical stage I nonseminomatous germ cell testicular cancer.
|
Urol Clin North Am
|
2007
|
0.94
|
|
35
|
Clinicians versus nomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer.
|
Urology
|
2013
|
0.94
|
|
36
|
Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
|
Urology
|
2005
|
0.90
|
|
37
|
Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience.
|
Ann Surg Oncol
|
2012
|
0.87
|
|
38
|
Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
Cancer
|
2012
|
0.86
|
|
39
|
Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.
|
Urology
|
2009
|
0.86
|
|
40
|
Prostate cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart.
|
Prostate
|
2012
|
0.85
|
|
41
|
The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment.
|
Urology
|
2009
|
0.84
|
|
42
|
Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis.
|
J Clin Oncol
|
2009
|
0.84
|
|
43
|
Management of poor-prognosis testicular germ cell tumors.
|
Indian J Urol
|
2010
|
0.83
|
|
44
|
Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.80
|
|
45
|
Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.79
|
|
46
|
Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400).
|
Urology
|
2008
|
0.79
|
|
47
|
Are nomograms needed in the management of bladder cancer?
|
Urol Oncol
|
2010
|
0.79
|
|
48
|
Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
|
Hematol Oncol Clin North Am
|
2011
|
0.77
|
|
49
|
Clinicopathologic characteristics of 23 cases of invasive low-grade papillary urothelial carcinoma.
|
Urology
|
2012
|
0.77
|
|
50
|
Presacral and retroperitoneal lymph node involvement in urothelial bladder cancer: results of a prospective mapping study.
|
J Urol
|
2011
|
0.76
|
|
51
|
Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.
|
Curr Urol Rep
|
2013
|
0.76
|
|
52
|
Systems pathology and predicting outcome after radical prostatectomy.
|
J Clin Oncol
|
2008
|
0.75
|
|
53
|
Words of wisdom. Re: Medium-term outcomes of active surveillance for localized prostate cancer.
|
Eur Urol
|
2013
|
0.75
|
|
54
|
The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation.
|
Urol Oncol
|
2011
|
0.75
|
|
55
|
Optimal use of prostate specific antigen for prostate cancer screening.
|
Vojnosanit Pregl
|
2013
|
0.75
|
|
56
|
Multidisciplinary management of patients with localized bladder cancer.
|
Surg Oncol Clin N Am
|
2012
|
0.75
|
|
57
|
Molecular markers in urologic oncology: prostate cancer.
|
Curr Opin Urol
|
2016
|
0.75
|